ERNA
|Eterna Therapeutics Inc
NASDAQ
USD 2.45
-0.18|-6.84%
Current Price
USD 2.45
Change
USD -0.18 (-6.84%)
P/E Ratio
Dividend Yield
Market Cap
11.23M
Volume
37,505
Open
USD 2.64
Previous Close
USD 2.63
52-Week High
USD 2.63
52-Week Low
USD 0.15
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Sanjeev Luther
Employees:6
Headquarters:Cambridge, USA
Website:www.ernexatx.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions